The US Department of Defense (DOD) has contracted biotechnology company Immunome for the development of biosynthetic convalescent plasma (BCP) for Covid-19. The $13.3m funding will see the company use its technology to quickly assess the wider immune response of recovered Covid-19 patients. It will do this by generating up to 10,000 B cell hybridomas from each patient and “isolate the most potent antibodies against this viral threat”. Immunome will use a method that will help deliver a process to produce a BCP alternative to convalescent plasma that could include four to six “highly potent anti-SARS-CoV-2 antibodies”.

The post Coronavirus company news summary – US DoD contracts Immunome for biosynthetic convalescent plasma appeared first on Army Technology.